Study tracks lifesaving drug use in C-Section bleeding emergencies
NCT ID NCT07278037
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 648 women who had heavy bleeding after a C-section. Researchers want to see how often the drug tranexamic acid (TXA) was given over the years, and whether more use led to better outcomes like less blood loss or fewer transfusions. The goal is to understand real-world use of a treatment that can cut death from bleeding by 31%.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tranexamic acid (TXA)
- What this could lead to
- If successful, this study could confirm that wider use of TXA after C-section bleeding improves survival and reduces complications.
- What could go wrong
- This is a retrospective chart review, not a controlled trial, so it can't prove cause and effect. Results may not apply to all hospitals or patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 648 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients underwent cesarean delivery with diagnosis of primary postpartum hemorrhage at Siriraj Hospital, Bangkok, Thailand
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Patients underwent cesarean delivery with primary postpartum hemorrhage Exclusion Criteria: 1. Gestational age at less than 24 weeks 2. Absence of the anesthetic record 3. Received tranexamic acid in the antepartum period 4. Blood loss less than 1,000 ml
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cesarean section complications are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Siriraj Hospital
RECRUITINGBangkoknoi, Bangkok, 10700, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One 2-Hour class may help new mothers manage Post-Cesarean pain
- A single class may help new mothers avoid Long-Term pain after C-Section
- Could a 20% lower anesthetic dose make C-Sections safer?
- Can a slower oxytocin infusion prevent dangerous blood pressure drops in C-Sections?
- A 12-minute video could save new mothers' lives – can it teach them to spot danger?
- Can a single dose extend Post-Cesarean pain relief?